Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1425-1429

  Kotaniemi, Kaisu ^a,b   Säilä, Hanna ^b   Kautiainen, Hannu ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adalimumab; Juvenile idiopathic arthritis; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; UVEITIS;

EID: 81055140827     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s23646     Document Type: Article

References (16)

1. Kanski JJ. Juvenile arthritis and uveitis. Surv Ophthalmol. 1990;34: 253-267.
2. Kotaniemi K, Savolainen A, Karma A, Aho K. Major review. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol. 2003;48:489-502.
3. Santos Lacomba M, Marcos Martín C, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
4. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45: 252-257.
5. Lovell D. Biological agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatric Drugs. 2004;6:137-146.
6. Braun J, Baraliakos X, Listing J, Sieoer J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447-2451.
7. Saurenmann RK, Levin AV, Rose JB, et al. Tumor necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982-989.
8. Vazquez-Cobian L, Flynn T, Lehman T. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572-575.
9. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319-324.
10. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritisassociated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34:1146-1150.
11. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47:339-344.
12. Trachana M, Pratsidou-Gertsi P, Pardalos G, et al. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011;40:101-107.
13. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31: 390-392.
14. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509-516.
15. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatology. 2004;31:2290-2294.
16. Sim KT, Venninig HE, Barrett S, et al. Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline. Ocul Immunol Inflamm. 2006;14:353-357.